AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

The Long-term Effect of Remote Ischemic Conditioning on Main Organs in ASVCD Patients With Very High Risks

Recruitingn/aAges 40 Years - anyAllGeneral Hospital of Shenyang Military Region
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Atherosclerotic cardiovascular disease (ASCVD) is a group of disorders sharing atherosclerosis as a common pathological basis, primarily affecting the heart, brain, kidneys, and other peripheral arteries, leading to clinical syndromes characterized mainly by arterial ischemia. It has become the group of diseases with the highest morbidity and mortality rates worldwide. Patients with very high-risk ASCVD face an even greater risk of recurrence. Previous studies have discovered that remote ischemic conditioning (RIC) has protective effects on major organs such as the heart, brain, and kidneys. Given the cardiorenal and cerebrovascular protective effects of RIC, the invesitgators believe that long-term remote ischemic conditioning is a promising approach to preventing the recurrence of ASCVD events. Based on this hypothesis, the investigators have designed a prospective, multicenter cohort

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Age over 40 years * Two or more prior major ASCVD events; OR one documented major ASCVD event with two or more of the following risk factors * signed informed consent Note๏ผš Definition of Major ASCVD Events: A. Acute coronary syndrome within the past year. B. History of myocardial infarction (not part of a new acute coronary syndrome episode). C. Ischemic stroke or history of ischemic stroke. D. Symptomatic peripheral artery disease, defined as intermittent claudication with an ankle-brachial index (ABI) \< 0.85, or prior limb revascularization or amputation. Risk factors: 1. Age โ‰ฅ65 y 2. Heterozygous familial hypercholesterolemia 3. History of prior coronary artery bypass surgery or percutaneous coronary intervention outside of the major 4. ASCVD event(s) 5. Diabetes mellitus 6. Hypertension 7. CKD (eGFR 15-59 mL/min/1.73 m2) 8. Current smoking 9. Persistently elevated LDL-C (LDL-C โ‰ฅ100 mg/dL \[โ‰ฅ2.6 mmol/L\]) despite maximally tolerated statin therapy and ezetimibe 10. History of congestive HF Exclusion Criteria: * Presence of severe neurological deficit (mRS score โ‰ฅ 3) * Uncontrolled severe hypertension (systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 110 mmHg despite medication) * Subclavian artery stenosis โ‰ฅ 50% or presence of subclavian steal syndrome * Severe hematological disorders or significant coagulation abnormalities * Contraindications to remote ischemic conditioning, such as severe soft tissue injury, fracture, or vascular injury in the upper limbs, or peripheral vascular disease in the distal upper limbs * Severe comorbid conditions with a life expectancy of less than 1 year * Participation in another clinical trial within the past 3 months or ongoing participation * Any other circumstances deemed by the investigator as unsuitable for participation in this clinical study.
๐Ÿ’Š

What it tests

  • remote ischemic conditioning
๐Ÿ“

Where

1 site
Department of Neurology, General Hospital of Northern Theater Command
Shenyang, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy